Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

1 of 0 completed with results

Key Signals

1 with results0

3Total

Not Applicable (1)

P 1 (1)

P 3 (1)

Terminated1

Withdrawn1

Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors

Showing all 3 trials